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Abstract
Background—Personalizing medical treatment often requires practitioners to compare multiple 
treatment options, assess a patient’s unique risk and benefit from each option, and elicit a patient’s 
preferences around treatment. We integrated these three considerations into a decision modeling 
framework for the selection of second-line glycemic therapy for type 2 diabetes.
Methods—Based on Multi-Criteria Decision Analysis, we developed a unified treatment decision 
support tool accounting for three factors; patient preferences, disease outcomes, and medication 
efficacy and safety profiles. By standardizing and multiplying these three factors, we calculated 
the ranking score for each medication. This approach was applied to determining second-line 
glycemic therapy by integrating: (i) treatment efficacy and side-effect data from network meta-
analysis of 301 randomized trials (N=219,277); (ii) validated risk equations for type 2 diabetes 
complications; and (iii) patient preferences around treatment (e.g., to avoid daily glucose testing). 
Data from participants with type 2 diabetes in the U.S. National Health and Nutrition Examination 
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Survey (NHANES 2003-2014, N=1,107) were used to explore variations in treatment 
recommendations and associated QALYs given different patient features.
Results—Patients at the highest microvascular disease risk had GLP-1 agonists or basal insulin 
recommended as top choices, while those wanting to avoid an injected medication or daily glucose 
testing had SGLT-2 or DPP-4 inhibitors commonly recommended, and those with major cost 
concerns had sulfonylureas commonly recommended. By converting from the most common 
sulfonylurea treatment to the model-recommended treatment, NHANES participants were 
expected to save an average of 0.036 quality-adjusted life-years per person (about a half month) 
from 10 years of treatment.
Conclusions—Models can help integrate meta-analytic treatment effect estimates with 
individualized risk calculations and preferences, to aid personalized treatment selection.
Keywords
personalized medicine; type 2 diabetes mellitus; network meta-analysis; shared decision-making
Introduction
“Shared decision-making”—or the joint selection of treatments between practitioners and 
patients—has been increasingly advocated in type 2 diabetes guidelines.1 Shared decision-
making involves incorporating data on treatment effectiveness and side-effects; individual 
patient risk and potential benefit; and a patient’s specific preferences into treatment 
decisions. Yet in practice, it is difficult to rigorously and formally calculate the 
individualized benefit or risk for multiple treatments and disease end-points, particularly 
during a brief patient encounter.1,2 Shared decision-making is particularly challenging for 
type 2 diabetes treatment decisions, which often involve choosing among numerous 
alternative second-line treatments to add to first-line metformin. In fact, primary care 
providers have identified that second-line diabetes treatment selection is a major source of 
anxiety and confusion, particularly in regions where specialty endocrinology consultation is 
limited.3,4 In this context, serious adverse events from type 2 diabetes treatments have 
become a leading cause of avoidable emergency department visits in the United States.5 
Improved decision support for clinicians may assist in choosing treatments that are 
beneficial and less risky for patients, while also helping patients engage with care decisions 
and thereby potentially remain more adherent to therapy.6-8
To assist in making treatment selections when there are multiple treatment options, 
guidelines have suggested incorporation of data from network meta-analyses (NMAs),4 
which take the data from all available randomized trials in a field, and assesses the impact of 
each treatment relative to other available treatments for each of several disease end-points, 
including treatment-related adverse events.9 To put these results into practice so as to 
calculate absolute risk reductions across numerous treatment options for an individual 
patient, relative risk reductions or odds ratios estimated through NMAs must be combined 
with personalized estimates of a patient’s pre-treatment risk.9-14 Treatment selection 
decisions can therefore be influenced by a patient’s age, biomarkers, co-morbid conditions, 
concurrent treatments, and related factors influencing pre-treatment risk for microvascular 
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and macrovascular outcomes as well as treatment-related adverse events. Validated risk 
equations15 may help make treatment selection more explicit by estimating the absolute risk 
and benefit from several treatment options given a specific patient’s clinical history, exam 
features, and biomarkers.16-18
Treatment options are also influenced by patient preferences, given that some patients are 
very concerned, for example, about weight gain, daily glucose testing, or having to take 
injected medications; these concerns may substantially influence treatment adherence.1 
Patient preferences may complicate treatment decisions, such as when choosing the optimal 
treatment for a patient with a high risk of hypoglycemia, high cardiovascular risk, limited 
income to afford a treatment with higher out-of-pocket cost, and difficulty with daily glucose 
testing.
Here, we developed a pilot modeling approach to select second-line type 2 diabetes 
treatments, integrating network meta-analytic data for treatment efficacy and side-effect, 
estimating individualized risk for a U.S. national sample, and simulating a diverse range of 
possible patient preferences. We hypothesized that our modeling strategy would lead to wide 
variations in the selection of different second-line treatments for glucose lowering in type 2 
diabetes, depending on complex combinations of patient characteristics and preferences.
Methods
Analytic approach
We constructed a unified treatment decision support tool by calculating treatment ranking 
scores accounting for three factors; patient preferences (e.g. out-of-pocket medication cost 
and requirement for glucose self-monitoring), disease outcomes (macrovascular and 
microvascular diseases), and medication efficacy and safety profiles (e.g. Hb1AC reduction 
and risks of hypoglycemia and adverse events. By standardizing these three factors into 0 to 
1 scales, and the multiplying, we calculated the ranking score for each medication. This 
approach (Figure 1) was applied to identify which treatments would be recommended for a 
given patient. Using data from participants with type 2 diabetes in the U.S. National Health 
and Nutrition Examination Survey (NHANES), we explored variations in treatment 
recommendations and associated QALYs given different patient features
Data sources
Data sources and outcome measures are summarized in Table 1. Treatment efficacy and 
side-effect data were obtained from a random-effects NMA of 301 randomized trials (N = 
118,094; Table 2).22 The data included six classes of glucose-lowering medications as 
potential second-line therapies to add to metformin: sulfonylureas, thiazolidinediones, 
DPP-4 inhibitors, SGLT-2 inhibitors, basal insulin, and GLP-1 receptor agonists. Treatment 
effects in terms of reducing or increasing the odds of each outcome measure were 
summarized in terms of odds ratios or standard mean differences for each medication class, 
versus placebo. Odds ratios or mean differences that were significant at the P<0.05 level 
were incorporated into our analysis to ensure that our results are robust (Table 2).
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Treatment effectiveness and adverse event rates on each class of therapy were calculated for 
participants aged 18 to 85 in the U.S. National Health and Nutrition Examination Survey 
(NHANES, 2003-2014) with type 2 diabetes mellitus [based on hemoglobin A1c ≥6.5% 
(47.5 mmol/mol), fasting plasma glucose ≥126 mg/dL (7.0 mmol/L), or self-reported 
diabetes treatment] who might be eligible for second-line treatment by virtue of having 
hemoglobin A1c >7.0% (53mmol/mol) on metformin treatment alone (N=1,107). Missing 
data (5% of the patient-level features detailed below) were not imputed, and only complete 
case analyses were performed, using NHANES survey weights to estimate a nationally-
representative U.S. sample (characteristics summarized in Appendix Table 1).
Outcomes
Absolute risk increase or decrease for each disease end-point was calculated by multiplying 
the NMA data (odds ratios for each outcome in Table 1, converted to relative risks based on 
U.S. outcome incidence rates19,20) by the baseline pre-treatment absolute risk estimate for 
each outcome. To incorporate changes in biomarkers (change in HbA1c or body weight), the 
absolute change was estimated by using the standardized mean difference in the biomarker 
from the NMA, and the baseline patient characteristic from NHANES. For costs, the 
absolute U.S. dollar increase in cost per 3 months of treatment was calculated. We also 
included indicator variables for whether the medication was parenteral or oral, and the 
number of times per week that glucose self-monitoring was recommended by a prior review.
21
Absolute pre-treatment risk for each disease end-point was estimated using the Risk 
Equations for Complications Of type 2 Diabetes (RECODe, see Appendix Text 1),15 which 
were previously validated in three randomized trial populations and two diverse longitudinal 
cohort studies in the U.S. ,20 and provide estimates for 10-year risk of myocardial infarction 
(MI, fatal or non-fatal), stroke (fatal or non-fatal, and hemorrhagic or ischemic), congestive 
heart failure, retinopathy (severe vision loss defined as <20/200 visual acuity by Snellen 
chart), neuropathy (pressure sensation loss on 10g monofilament testing), nephropathy (renal 
failure/end-stage renal disease), and all-cause mortality. The RECODe equations required 
data on age, sex, race/ethnicity (Black, Latino/Hispanic, and other), current tobacco 
smoking, systolic blood pressure, history of cardiovascular disease (MI or stroke), current 
blood pressure-lowering drugs, current statin therapy, current anticoagulant use other than 
aspirin (e.g., warfarin or non-vitamin K antagonist oral anticoagulant), current glycemic 
treatment, hemoglobin A1c (HbA1c), total and high-density lipoprotein cholesterol, serum 
creatinine, and urine microalbumin to creatinine ratio.
Additional outcomes included the risk for hypoglycemia, for which pre-treatment risk on 
metformin alone (versus the odds on the above therapies) was calculated conditional on 
patient age and HbA1c, using data from the U.S. Centers for Disease Control and Prevention 
(CDC; Appendix Table 2).23
Another outcome of interest was treatment-related adverse events other than hypoglycemia, 
including severe nausea, fluid retention (edema), diarrhea, or rash that were fatal or life-
threatening, that resulted in clinically significant or persistent disability, that required or 
prolonged a hospitalization, or that were judged by trial investigators to represent a clinically 
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significant hazard or harm (coded per the Medical Dictionary for Regulatory Activities). The 
baseline risk of treatment-related adverse events was estimated as an incidence rate of 0.016 
from the metformin-only subset of participants in the standard glycemic therapy arm of the 
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial.24
Relative decreases and increases in outcome risk across treatment options
The input NMA data used in this assessment (Table 2) indicated no significant reduction in 
the risk of MI or stroke from the therapies considered (n.b., changed in sensitivity analyses), 
but significantly increased risk of hypoglycemia from sulfonylureas and basal insulin, and 
substantial reduction in body weight from GLP-1 agonists and SGLT-2 inhibitors. Costs 
were highest for GLP-1 agonists, followed by SGLT-2 inhibitors. Glucose self-monitoring 
requirements were highest for basal insulin.
Treatment features considered for patient preferences
Additional patient-relevant features of each medication were considered, and were selected 
because they appeared as important to treatment selection on a previously-published U.S. 
survey.25-27 These included: whether the treatment was parenteral or oral, degree of average 
body weight gain or loss (in kilograms), change in HbA1c (absolute percentage point 
reduction), medication cost (in 2017 U.S. Dollars based on average standardized out-of-
pocket price to consumers across insurance types), and recommended times per week for 
glucose self-monitoring (Table 1).28
Risk score calculation
The model involved calculation of a partial value function (Appendix Text 2 and Appendix 
Figure 1), which transforms absolute ranges of each outcome values that is continuous 
(disease end-point risk, HbA1c, body weight, cost, and self-monitoring per week) into a 0 




B − W , W < x < B
0, x≤W
,
where B is the best and W is the worst possible absolute risk decrease or increase estimate 
for each outcome among the treatments, and x is the absolute risk changes expected from the 
treatment being evaluated for the given individual patient. The modeling strategy used the 
approach adopted from Multi-Criteria Decision Analysis (MCDA),29-35 which produced a 
treatment score over N outcomes calculated as:
∑iN pre f erence weighti × normalized disability weighti × u(imed),
such that the partial value function enabled different outcomes (reduction in HbA1c, 
increase in rate of adverse events) to be fairly compared across the range of possible values, 
and combined these scores into a treatment ranking where preference weights reflected the 
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importance of the outcome to a given individual. The treatment score calculation handles 
multiple outcomes by assuming additivity of the product of patient preference weight, 
normalized disability weight, and the partial value function, u(med). The preference weights 
were on a scale from 0 (not important) to 1 (very important; Appendix Figure 1). To account 
for relative severity/importance of decision outcomes, normalized disability weights 
associated with each outcome were incorporated based on prior comprehensive surveys of 
quality-adjusted disutility (Appendix Table 3), separately from patient preference weights.
36-40 For example, if a patient place preference weights of 1 (very important) to both 
avoiding cardiovascular diseases and cost, the normalized weights would adjust the weights 
so that the ranking score considers avoiding CVD more seriously than avoiding higher cost 
with higher disability weights placed on CVD; the ranking score becomes less sensitive to 
avoiding higher cost as compared to avoiding stroke (Appendix Table 4). We adjust for both 
the severity of the condition (disability weights) and how much a patient ‘cares’ about the 
risk of experiencing that condition or not (preference weights, reflecting factors such as risk 
aversion and discounting), which are conceptually distinct. An automated online decision 
support tool was also produced for clinical application, where patients could input their 
preferences around major treatment-related variations.41 Normalized disability weights 
associated with outcomes were fixed in the calculation, so that patients would only expect to 
adjust their preference weights (not enter disutility values for each outcome) in the 
interactive decision support tool.
We assessed how differences among NHANES participant features and potential preferences 
could change the medication scores, and which treatments were selected as having the 
highest scores and for what reasons. We varied patient risk profiles, to examine in particular 
how medication scores differed across patients with lower versus higher baseline HbA1c, 
cardiovascular disease risk factors, and age, both individually and in concert with different 
preferences. In each simulated case, we performed Monte Carlo sampling 10,000 times from 
estimated Gaussian probability distributions around the treatment effect measures in the 
NMAs to estimate 95% confidence intervals. We selected Gaussian distributions because the 
NMA data presented means and standard deviations from an estimation procedure that 
generated a Gaussian outcome estimate.
Sensitivity analyses
We incorporated findings from recent trials not included in the base-case meta-analyses, 
modifying estimates of the impact of some glucose-lowering medications on cardiovascular 
outcomes, and including additional secondary outcomes (Table 2). Specifically, we 
incorporated new evidence of cardiovascular risk reduction among the agents studied in 
newer trials, with GLP-1 agonists having an odds ratio of 0.87 (0.76, 0.99) for non-fatal 
stroke, and SGLT-2 inhibitors having an odds ratio of 0.86 (0.77, 0.97) for non-fatal MI.42 
We used treatment effect measures for only non-fatal cardiovascular outcomes to ensure that 
the outcomes are mutually exclusive with all-cause mortality. Because GLP-1 agonists and 
SGLT-2 inhibitors were both found to significantly lower the risks of heart failure and 
SGLT-2 inhibitors were found to additionally lower the risk of all-cause mortality, heart 
failure and all-cause mortality were included in the sensitivity analyses. The odds ratio of 
all-cause mortality was 0.88 (0.81, 0.94) for GLP-1 agonists.42 The odds ratios of all-cause 
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mortality was 0.80 (0.71, 0.89) and of heart failure was 0.62 (0.52, 0.72) for SGLT-2 
inhibitors.42 We included these estimates in the sensitivity analysis and not the baseline 
modeling, following guidelines for using unaltered meta-analysis data in a baseline 
modeling assessment,43 and because the newer NMA incorporating these endpoints did not 
comprehensively consider other medication classes and other disease end-points or side-
effects.42
Analyses were performed in R (v. 3.3.3, The R Foundation for Statistical Computing, 
Vienna), using the code linked to the Appendix for reproduction and extension.
Results
Treatment rankings based on patient features
If patients had no differential preferences around willingness to gain weight, inject 
medications, perform glucose self-monitoring, avoid treatment-related side-effects or incur 
higher out-of-pocket drug costs, then their relevant biomarkers and personal features entirely 
determined their treatment recommendations via the model. Appendix Table 5 provides 
examples of four different NHANES participants with different features and either high or 
low cardiovascular risk and high or low microvascular risk. As shown, GLP-1 agonists and 
basal insulin were recommended as top-ranked medications among people with heightened 
microvascular risks, due to the input NMA ranking them as most effective relative to the 
other choices for realized HbA1c reduction. Note that the input NMA did not yet consider 
cardiovascular risk trials recently revealing potential benefits of GLP-1 agonists and SGLT-2 
inhibitors in reducing cardiovascular risks, congestive heart failure exacerbations in specific; 
these were considered in the sensitivity analysis.
Treatment rankings based on patient preferences
Figure 2 provides an estimate of the frequency with which different treatments were 
recommended by the MCDA-based method to each participant in the NHANES study if 
each participant had one particular preference among those available from the NMA (avoid 
parenteral treatments; weight gain; high medication cost; or glucose self-monitoring), and 
had no differential preference regarding the other treatment factors. As shown, patients 
wanting to avoid parenteral treatment and daily glucose testing had SGLT-2 inhibitors or 
DPP-4 inhibitors recommended most commonly, while those wanting to avoid weight gain 
were recommended a GLP-1 agonist most commonly, while those with major cost concerns 
often had sulfonylureas recommended. Notably, participants who had multiple preferences 
had different treatment rankings based on those combined preferences and their personalized 
risk/benefit scores. For example, participants with high cost considerations who were also at 
high risk for hypoglycemia often had thiazolidinediones recommended instead of 
sulfonylureas (Appendix Table 6).
Absolute decreases and increases in outcome risk across treatment options
We estimated absolute risk decreases and increases for the NHANES population, when each 
individual was given the medication ranked as their best option by the model if participants 
only considered reducing microvascular risk as much as possible in their treatment decision-
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making. The baseline pre-treatment risk among the NHANES population over 10 years was 
10.5% for MI (95% CI: 9.9, 11.0), 4.0% for stroke (95% CI: 3.7, 4.2), 6.6% for nephropathy 
(95% CI: 6.4, 6.8), 12.5% for neuropathy (95% CI: 12.0, 12.9), and 8.6% for retinopathy 
(95% CI: 8.3, 8.9).
If reducing microvascular risk was the primary consideration, the most commonly-
recommended treatment was GLP-1 agonist, followed by basal insulin, when the decision 
was based on the input NMA data. Under this scenario, the absolute 10 year-risk of 
microvascular diseases decreased by 2.1 % (95% CI: −2.2, −2.0), 1.1 % (95% CI: −1.2, 
−1.1), and 0.9 percentage points (95% CI: −0.9, −0.8) for neuropathy, retinopathy, and 
nephropathy outcomes, respectively. Absolute HbA1c reduction was −1.1% (−11.5 mmol/
mol; 95% CI: −1.3, −0.8). Body weight was reduced by 0.37 kg (95% CI: −0.61, −0.13), and 
the medication cost incurred was $633 (95% CI: 499, 766) per 3 months.
We compared the estimated the quality-adjusted life-years (QALYs) saved over 10 years 
(with 1-year increment) among the NHANES population if they converted from the most 
common second-line treatment of a sulfonylurea to the most-recommended treatment for 
them by the MCDA-based model if they were preference agnostic. The treatment was given 
to simulated patients if HbA1c is greater than 6.5%. We estimated that the modeling 
approach would save at least 0.036 (95% CI: 0.032, 0.040) QALYs per person (about a half 
month) among NHANES participants for 10 years of treatment by switching to the MCDA-
based recommended medication (typically a GLP-1 agonist). Those at high risk of 
macrovascular and microvascular diseases received the most benefits with incremental 
QALYs of 0.066 (95% CI: 0.056, 0.076) and 0.057 (0.049, 0.064) per person, respectively 
(Table 3), typically through selection of a SGLT-2 inhibitor.
Sensitivity analyses results
When the most optimistic cardiovascular disease odds ratios from a recent meta-analysis 
(including results from the LEADER, EMPA-REG, CANVAS/CANVAS-R, and 
SUSTAIN-6 trials) were considered,42,44-46 we found that people with high cardiovascular 
risk would be treated with SGLT-2 inhibitors more frequently, followed by GLP-1 agonists 
(Table 4). For people with low cardiovascular risk but high microvascular risk, GLP-1 
agonists would be recommended most, followed by SGLT-2 inhibitors.
When secondary outcomes (heart failure and all-cause mortality) were included as decision 
outcomes, and if reducing the composite of macrovascular (MI, stroke, and heart failure), 
microvascular, and all-cause mortality risk was the primary consideration, the most 
commonly recommended treatment was a SGLT-2 inhibitor due to its efficacy in reducing 
cardiovascular and all-cause mortality risk, followed by a GLP-1 agonist. Under this 
scenario, the absolute 10 year-risk among NHANES participants decreased by an average of 
1.68 % (95% CI: −1.76, −1.59) for MI and by 3.39 % (95% CI: −3.62, −3.16) for heart 
failure among the NHANES population. The 10-year microvascular disease risk decreased 
by an average of 1.65 % (95% CI: −1.71, −1.59), 0.94 % (95% CI: −0.98, −0.90), and 0.66% 
(95% CI: −0.69, −0.62) for neuropathy, retinopathy, and nephropathy, respectively. Absolute 
HbA1c reduction was −0.8% (−9.09 mmol/mol; 95% CI: −1.2, −0.5) on average. Body 
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weight was reduced by 0.16 kg (95% CI: −0.32, −0.05) on average, and the medication cost 
incurred was $413 (95% CI: 410, 416) per 3 months per person.
After incorporating secondary outcomes in treatment recommendation, we estimated that the 
MCDA-based approach would save at least 0.064 (95% CI: 0.061, 0.067) QALYs per person 
among NHANES participants. Those at high risk of macrovascular and microvascular 
diseases received the most benefits with incremental QALYs of 0.118 (95% CI: 0.108, 
0.128) and 0.096 (0.089, 0.107) per person, respectively (Table 3). In each scenario, the 
benefits in terms of QALY gains were around twice those accruing from current second-line 
treatment.
Discussion
We developed a modeling approach to apply a MCDA modeling framework to the 
assessment of add-on glycemic therapy for type 2 diabetes care as a pilot study. We were 
able to parameterize complex interrelationship between treatment benefits, side-effects, and 
patient preferences that may better allow clinicians to implement shared decision-making. 
This study critically offers a generalizable strategy to incorporate complex quantitative 
network meta-analytic data that enables comparisons across available treatments; 
individualized risk/benefit estimates; and patient preferences to aid in personalized treatment 
selection.
The modeling approach to decision support offers advantages over prior decision support 
tool frameworks. First, the approach incorporates NMA results to provide 
objectivequantitative comparisons across all available treatment options.29-33 An advantage 
of this approach is that the analysis can be rapidly updated as new trials and meta-analyses 
are released, as we illustrated in sensitivity analyses. Second, the approach incorporates 
validated individual risk calculations based on patient features, allowing the treatment 
ranking to be influenced by formal multi-variable risk assessment rather than a single 
biomarker alone or a loose gestalt of a patient’s clinical profile. Since multiple factors 
influence a person’s risk for disease endpoints, and therefore their absolute risk reduction 
from different treatments, it can be complicated to account for all pertinent patient features 
when selecting a patient’s treatment. Third, the modeling approach can be generalized to 
several other treatment decisions, not just to the choice of second-line diabetes treatment 
selection by incorporating treatment efficacy and side-effects comparison data from network 
meta-analysis and individualized risk/benefit equations for other disease outcomes Hence, 
the approach may be applicable to a wide range of other problems that require consideration 
of numerous outcomes and treatment options incorporating patient preferences. The open-
sourced code provided with this manuscript permits replication and extension of the 
approach to other clinical questions for which NMA data are increasingly available. The 
online decision tool also enables clinical application.41
Our study has limitations inherent to modeling based on secondary data sources. First, most 
trials of diabetes therapy include only short follow-up periods (ranging between 6 and 79 
months),22 which means data from the NMA must be extrapolated to longer time periods. 
Second, in clinical practice, healthcare costs vary considerably by country and, within 
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countries, by insurance plan. The inclusion of costs presents an important ethical 
consideration that requires further discussion. On one hand, having higher-risk drugs (e.g., 
sulfonylureas, a common source of disagreement) by incorporating cost into the weights can 
be seen as discriminatory against lower-income patients for whom cost is a genuine 
treatment factor. This raises an ethical issue of ensuring the optimal treatment choice for 
patients independent of affordability. On the other hand, in most parts of the world, out-of-
pocket expenses are a disutility, and even in countries with universal health coverage, health 
technology agencies select thresholds of benefit per unit cost. Moreover, while this decision 
support tool provides support for shared decision making between patients and clinicians, 
from a payer’s perspective, this decision support framework needs to be updated with 
different cost data and other decision criteria in decision making processes. Third, we 
consider a broad, but not exhaustive, set of patient preference possibilities in our 
demonstration analysis; additional patient preferences could be elicited systematically for 
future iterations, but how to best elicit patient preferences across patients with diverse health 
literacy and numeracy remains a matter of investigation. Fourth, we intentionally used 
published and statistically significant NMA data in the baseline assessment and left the 
addition of recent major cardiovascular risk reduction trials to a sensitivity analysis; this was 
to ensure that our results are conservative by including only treatment effect measures that 
are statistically significant (p<0.05), and to follow guidelines for using unaltered meta-
analysis data in a baseline modeling assessment,43,47-49 but also to illustrate how new major 
trials can dramatically alter treatment rankings and be rapidly incorporated into the analysis. 
We note that in our sensitivity analysis of GLP-1 agonists and SGLT-2 inhibitors, we 
assumed relative risk reductions in cardiovascular outcomes proportional to baseline risk, 
though the cardiovascular risk reduction trials themselves were limited to patients with high 
cardiovascular disease risk. Other limitations include that are inherent with network meta-
analysis include that participant characteristics that may affect the relative efficacy of 
interventions are similar across groups.42 Moreover, because the treatment ranking 
calculation is performed in relative scale within the available options based on NMA data, a 
decision maker assigns preferences on a standardized relative scale rather than absolute 
scales in quantitative terms. Fifth, we compared the estimated the QALYs saved over 10 
years among the NHANES population if they converted from the most common second-line 
treatment of a sulfonylurea to the most-recommended treatment for them by the MCDA-
based model if they were preference agnostic. The durability of sulfonylureas may be 
limited over time, but the ADOPT trial is the only randomized trial to our knowledge that 
provides evidence of slightly more substantial durability of rosiglitazone than metformin 
than glyburide, but only as monotherapies rather than as add-on therapy to metformin.50 The 
GRADE study planned for completion in 2021 may provide the definitive data necessary for 
addressing this question.51 Lastly, while MCDA-based modeling may help clinicians and 
patients understand their treatment options, the tool should not yet be implemented in 
practice as several other aspects of theory must be worked out and tested before such 
utilization. The tool aggregates many aspects of care that may be disaggregated in future 
visualizations. Additionally, there are non-quantifiable factors, beyond the considered 
decision criteria, such as ethical and social factors, which need to be accounted for when 
making the final treatment decision. Therefore, our modeling strategy can serve as an aid for 
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informed shared decision making, but should not be used as a prescription tool in the current 
form.
The next logical step for this work is to conduct NMA studies that help distinguish between 
individual drugs, rather than only between drug classes. An important limitation of all 
NMAs on glucose-lowering medications to date is that they treat an entire class of drugs 
together for comparison, without distinguishing within-class, between-drug differences. For 
example, while hypoglycemia is incorporated in terms of the multiplicative effect by class, 
any specific side effects that are drug-specific but not generalizable to the class at are not yet 
included and could be in the future with revised NMA data that includes specific drugs. An 
additional direction for future research is to further individualize treatment recommendations 
by NMAs based on individual participant data, which may go beyond the average summary 
effects presented and incorporate heterogeneous treatment effect estimates based on patient 
features. A third direction we intend to pursue is to identify how alternative communication 
strategies for the decision support tool, and alternative strategies for including and eliciting 
patient and provider preferences, may assist in decision-making. In addition, while we 
wished to ensure that our results are conservative by including only treatment effect 
measures from NMA that are statistically significant (p<0.05), in the future we could sample 
from a broad range of distributions including non-significant ranges. Using a Bayesian 
approach and propagating uncertainty may help clarify the distributions around drug 
rankings.
MCDA is a modeling strategy that may help to address an age-old clinical problem: how 
best to integrate information regarding treatment benefits and side effects, individualized 
risk, and patient preferences. The results of this study may help provide a framework to 
synthesize randomized trial data, personalized risk estimates, and individual patient 
preferences into a unified platform to support shared decision-making in type 2 diabetes 
care, and other major medical treatment decisions. The framework to synthesize randomized 
trial data, personalized risk estimates, and individual patient preferences into a unified 
platform to support shared decision-making can theoretically be applied to other major 
medical treatment decisions where there are multiple treatment options without a clear 
‘winning’ therapy that is both the most effective and with the least side-effects. This applies 
to current therapies for heart disease, mental illness, and rheumatological disease, among 
others.
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Text 1. Risk Equations for Complications of type 2 Diabetes (RECODe)
Risk equations for microvascular and cardiovascular complications of type 2 diabetes were 
developed using individual participant data from a large intervention study and validated in 
two randomized trials and two longitudinal cohort studies.1,2 The following table provides 
the RECODe coefficients.








Age, years 0.04363 0.02896 0.03022 0.02285 −0.01938
Women −0.20660 − 0.00326 −0.1868 0.2264 −0.01129
Ethnicity
Black −0.11630 0.2716 −0.09448 −0.1677 0.08812
Hispanic or Latino 0.2338
Clinical features
Tobacco smoking, current 0.2358 0.1665 0.1483
SBP (mmHg) −0.00514 0.01659 0.00456 0.00824 0.00303
History of CVD 0.9618 0.4138 0.26672 0.1127 −0.02164
Drug use
BP lowering drugs −0.12480 0.1598 0.18192 0.06393 −0.07952
Statins 0.04699 − 0.18870
Anticoagulants 0.544 − 0.13870 0.03199
Oral diabetes drugs −0.25747 −0.2349 −0.1256
Biomarkers
HbA1c, % 0.2135 0.3365 0.18866 0.1449 0.1369
Total cholesterol, mg/dL 0.00019 0.00171 0.00219 −0.00017 −0.00111
HDL cholesterol, mg/dL −0.01358 − 0.00639 −0.00539 0.00545 0.00629
Serum creatine, mg/DL 0.08027 0.5955 0.604442 0.6947 0.8609
Urine albumin:creatine ratio, 
mg/g
0.00042 0.0003 0.0002 0.00036
The 10-year risk of an outcome can be computed as 1 – λ^exp (Σ (βx) – mean (Σ (βx))), 
where β are the equation coefficients and × are the values for each covariate for an 
individual patient within the cohort under study, λ values are: 0.973 for renal failure or end-
stage renal disease (nephropathy), 0.921 for retinopathy, and 0.870 for neuropathy and 
corresponding values of mean (Σ (βx)) were 0.23 for renal failure/end-stage renal disease 
(nephropathy), 4.56 for retinopathy, and 4.75 for neuropathy. For CVD outcomes, λ values 
were 0.93 for fatal or non-fatal MI and 0.98 for fatal or non-fatal stroke, and mean (Σ (βx))) 
values were 2.92 for fatal or non-fatal MI and 6.96 for fatal or non-fatal stroke.
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For example, a 60-year-old non-smoking white man with systolic blood pressure 140 mm 
Hg, without history of cardiovascular disease, not on any medications, and with HbA1c of 
8%, total cholesterol of 190 mg/dL, HDL of 50 mg/dL, serum creatinine 1.1 mg/dL, and 
urine microalbumin:creatinine ratio of 10 mg/g would have a risk of renal failure/end-stage 
renal disease of 1–0.973^exp(−0.01938*60 + 0.003027*140 + 0.1369* 8-0.001112*190 
+ 0.006289* 50 + 0.8609*1.1 + 0.000362*10–0.23) = 0.085 or a 8.5% 10-year risk, where 
0.23 is the mean(Σ(βx)).
Text 2. Patient preference and normalized disability weights
A partial value function captures a decision maker’s preferences on a standardized scale.3 It 
transforms values selected along a slider bar (from least important to most important) to the 
range 0-1 (lowest preference weight to highest preference weight). Partial value functions 
can be linear or non-linear depending on a decision maker’s desirability of scale values. For 
example, in case of serious adverse events, if a decision maker perceives an increase in 
serious adverse event rates from 0% to 1% is the same as an increase from 1% to 2%, the 
partial value function is linear. However, if a decision maker is less willing to take an 
increase from 0% to 1% than 1% to 2%, the partial value function would be concave. In this 
study, we assumed partial value functions to be linear for each decision criterion.
Patient preference
Patients can determine a set of weights for each decision criterion. For example, the scale of 
hypoglycemia is 2% to 17% and the scale of if HbA1c is −3.5 to −1.0. If a patient assigns 
weights of 0.4 to hypoglycemia and 0.8 to HbA1c, the decrease in HbA1c is two times more 
important than the increase in hypoglycemia for the patient.
In our decision support tool using this model, there were two sets of weights, (1) fixed 
weights to account for relative severity of disease complications (e.g., myocardial infarction, 
stroke, etc.) using normalized disability weights associated with each of the outcomes 
(Appendix Table 3), and (2) patient preference weights to account for features of treatments 
(e.g., cost, parenteral versus oral, etc.) that a patient could vary from “not important” (weight 
of 0) to “extremely important” (weight of 1). For example, if a patient place preference 
weights of 1 (very important) to both avoiding cardiovascular diseases and cost, the 
normalized weights would adjust the weights so that the ranking score considers avoiding 
CVD more seriously than avoiding higher cost with higher disability weights placed on 
CVD; the ranking score becomes less sensitive to avoiding higher cost as compared to 
avoiding stroke (Appendix Table 4). Normalized disability weights were built in the 
calculation that patients would be only expected to adjust their preference weights. 
Medication rankings purely based on patient preferences without normalized disability 
weights considered are presented in Appendix Table 7.
To illustrate how medication ranking is calculated, we present a case with two decision 
criteria (HbA1c reduction and serious adverse events) and two medication options 
(Sulfonylurea and SGLT-2 inhibitors). Suppose the absolute scale ranges for HbA1c 
reduction and serious adverse events are (−3.5, −1.0) and (0.015, 0.020), respectively. 
Suppose a patient only considers HbA1c reduction and avoiding serious adverse events in 
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the decision-making process for the dual add-on therapy to metformin, with weights 0.7 to 
HbA1c reduction and 0.3 to avoiding adverse events. Then, the medication ranking score is 
calculated as a weighted average of the transformed treatment effect measures as shown in 
Appendix Figure 1.
Text 3. Illustration of converting relative measures into absolute scales




Systolic blood pressure (mmHg) 139
Statin use 0
Anticoagulant use 0
BP medication use 0
Currently smoking 0
Diabetes 1
Oral diabetes medication use 0
Total cholesterol (mg/dL) 205 (5.3 mmol/L)
HDL cholesterol (mg/dL) 76 (2.0 mmol/L)
Hemoglobin A1c (%) 5.8 (39.9 mmol/mol)
Serum creatinine 0.9




The person’s macrovascular and microvascular disease risks can be calculated using 
RECODe equations:






Then the absolute baseline risk for all decision criteria considered would be as following 
(outcomes using standard mean difference as treatment effectiveness based on the network 
meta-analysis):
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After incorporating treatment efficacy and safety data of different add-on dual therapy 
medication options (assuming this person gets metformin as first-line therapy), the absolute 
min/max possible ranges are calculated for each decision criteria. Each second-line 
medication option would fall within these absolute ranges, and the risk scores will be 
calculated after transforming these ranges into 0-1 scales:
Outcome Best Worst
Adverse_event 1.1% 2.6%
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Appendix Figure 1. Ranking score calculation
Outcome1:HbA1c reduction
Outcome2: Serious adverse events
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Partial value functions transform absolute scales into 0-1 scales. Medication ranking score is 
calculated as a weighted average of transformed values accounting for patient preference 
weights and normalized disability weights for each decision criterion
ScoreSGLT‐2 =
preference weightHbA1c
∗normalized disability weightHbA1c ∗ u(HbA1cSGLT‐2) +
preference weightadverse
∗normalized disability weightadverse ∗ u(AdverseSGLT‐2)
Scoresulfonylurea =
preference weightHbA1c
∗normalized disability weightHbA1c ∗ u(HbA1csulfonylurea) +
preference weightadverse
∗normalized disability weightadverse ∗ u(Adversesulfonylurea)
Here, preference weight will be determined by the decision maker through the decision 
support tool in Appendix Figure 2.
Figure 2. User interface of the online decision support tool 4
(A)Risk calculator tab for absolute pre-treatment risk of each outcome
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(B) Patient preference elicitation tab with individualized treatment rankings
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Table 1. NHANES population characteristics (2003-2014)
Profiles of patients with type 2 diabetes mellitus in the National Health and Nutrition 
Examination Survey (NHANES, N = 35,034, 2003-2014) were used to explore sensitivity of 
treatment rankings to different patient features and preferences
Analyses were restricted to the subset (N=1,107) that might be eligible for second-line 
treatment by virtue of having hemoglobin A1C ≥7% (53 mmol/mol), on metformin 
treatment alone. Missing data (60.3% of the patient-level features detailed below) were not 
Choi et al. Page 19













imputed, and only complete case analyses were performed, using NHANES survey weights 
to estimate a nationally-representative sample
Characteristics [Mean or % (sd)] NHANES (2003-2014, N=1,107)
Demographics




Hispanic or Latino 13.4% (1.0)
Clinical features
Tobacco smoking, current 17.3% (1.1)
SBP (mmHg) 130.1 (19.5)
History of CVD 20.6% (1.2)
Drug use
BP lowering drugs 66.2% (1.4)
Statins 9.3% (0.8)
Anticoagulants 1.4% (0.3)
Oral diabetes drugs (metformin) 27.1% (1.3)
Biomarkers
HbA1c, (%) 7.2 (1.6) [55 (12) mmol/mol]
Total cholesterol, mg/dL 182.1 (41.8) [4.72 (1.1) mmol/L]
HDL cholesterol, mg/dL 49.2 (14.5) [1.5 (0.4) mmol/L]
Serum creatinine, mg/dL 1.0 (0.4) [88.4 (35.4) umol/L]
Urine albumin:creatinine ratio, mg/g 23.2 (26.2)
Table 2. Baseline risk for symptomatic hypoglycemia
Incidence per 1,000 diabetic adults5
Age Group
18–44 45–64 65–74 75+
Rate Std Error Rate Std Error Rate Std Error Rate Std Error
14.4 1.1 10.0 0.5 15.1 0.9 27.6 1.8
Incidence conditioned on baseline hemoglobin A1c.6
Baseline HbA1c (vs ≤5.6%) OR (95% CI)
5.7% - 6.4% 1.12 (0.81-1.54)
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Baseline HbA1c (vs ≤5.6%) OR (95% CI)
6.5%-7.0% 0.99 (0.77-1.28)
Table 3. Disutility weights for disease outcomes
By disease outcome,
Disease Disutility weight Sources









In addition to preference weights assigned by the patient/clinicians, disutility weights were 
assigned and fixed weights to disease outcomes normalized by the weight of MI (the highest 
disutility weight). Disutility weight of obesity was applied to non-clinical outcomes; body 
weight gain, injection, daily glucose testing, and cost to account for relative severity/
importance of outcomes. In microsimulations, the average time-weighted disability value 
was used to estimate QALYs lost due to MI.
Table 4. Individual example with and without normalized disability weights
A preference weight of 1 was assigned to cost and cardiovascular diseases (myocardial 
infarction and stroke). The rest of the outcomes were not considered important in this 
example.
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Table 5. Individual example (Base-case)
Preference weights: the composite outcome of macrovascular and microvascular endpoints 
were considered important, accounting for the disability weights associated with disease 
outcomes (Appendix Table 3), and using the base-case network meta-analysis for input data 
(not accounting for recent trials with reduced cardiovascular disease from SGLT-2 or GLP-1 
agents). The rest of the outcomes were not considered in this example.
variable Person 1 Person 2 Person 3 Person 4
Sex Female Female Male Male
Age 47 44 63 66
Race Hispanic Black White Black
SBP (mmHg) 137 95 128 116
Statin use No No No No
Anticoagulant use No No No No
BP medication use No Yes Yes Yes
Currently smoking No Yes No No
Oral diabetes medication 
use
No No No No
Total cholesterol (mg/dL) 188 (4.9 mmol/L) 106 (2.7 mmol/L) 195 (5.1 mmol/L) 122 (3.2 mmol/L)
HDL cholesterol (mg/dL) 44 (1.1 mmol/L) 36 (0.9 mmol/L) 69 (1.8 mmol/L) 25 (0.6 mmol/L)
Hemoglobin A1c (%) 7.5 (58.5 mmol/mol) 9.1 (76.0 mmol/mol) 8.0 (63.9 mmol/mol) 11.4 (101.1 mmol/mol)
Serum creatinine (mg/DL) 0.6 (53.0 μmol/L) 0.7 (61.9 μmol/L) 1.9 (168.0 μmol/L) 2.32 (205.1 μmol/L)
Urine albumin creatinine 
ratio (mg/g)
54.2 7.6 68.8 60.0
CVD history Yes Yes No Yes
CVD risk (10-yr risk, %) Low High Low High
  Myocardial infarction 8 12 7 56
  Stroke 2 2 5 34
Microvascular risk (10-
yr risk, %)
Low Low High High
  Nephropathy 8 7 23 58
  Retinopathy 6 5 17 26
  Neuropathy 7 7 16 23
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Drug ranking scores were normalized by the best ranking score. Score of 1 refers to the best ranking score, and the scores 
for other drugs are ranking scores relative the best ranking score. 95% confidence intervals were generated based on the 
uncertainty around the treatment effect estimates from the network meta-analysis. TZD: Thiazolidinedione; SU: 
Sulfonylurea; GLP-1RA; GLP-1 agonist; SGLT-2-I; SGLT-2 inhibitor; DPP-4-I; DPP-4 inhibitor
Table 6. Individual example with differences in preference weights
Preference weights: the composite macrovascular and microvascular endpoints were 
considered important in this example, accounting for the disability weights associated with 
disease outcomes (Appendix Table 3), and using the base-case network meta-analysis for 
input data (not accounting for recent trials with reduced cardiovascular disease from SGLT-2 
or GLP-1 agents). A preference weight of 1 was assigned to injection and daily glucose 
testing. The rest of the outcomes were not considered important in this example.
Covariate Person 1
No consideration for hypoglycemia
(w=0)










SBP (mmHg) 137 137
Statin use No No
Anticoagulant use No No
BP medication use No No
Currently smoking No No
Oral diabetes medication use No No
Total cholesterol (mg/dL) 188 (4.9 mmol/L) 188 (4.9 mmol/L)
HDL cholesterol (mg/dL) 44 (1.1 mmol/L) 44 (1.1 mmol/L)
Hemoglobin A1c (%) 7.5 (58.5 mmol/mol) 7.5 (58.5 mmol/mol)
Serum creatinine (mg/DL) 0.6 (53.0 μmol/L) 0.6 (53.0 μmol/L)
Urine albumin creatinine ratio (mg/g) 54.2 54.2
CVD history Yes Yes
CVD risk (10-yr risk, %) Low Low
  Myocardial infarction 8 8
  Stroke 2 2
Microvascular risk (10-yr risk, %) Low Low
  Nephropathy 8 8
  Retinopathy 6 6
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No consideration for hypoglycemia
(w=0)





High consideration for cost
(w=1)
  Neuropathy 7 7



























Drug ranking scores were normalized by the best ranking score. Score of 1 refers to the best ranking score, and the scores 
for other drugs are ranking scores relative the best ranking score. 95% confidence intervals were generated based on the 
uncertainty around the treatment effect estimates from the network meta-analysis.
TZD: Thiazolidinedione; SU: Sulfonylurea; GLP-1RA; GLP-1 agonist; SGLT-2-I; SGLT-2 inhibitor; DPP-4-I; DPP-4 
inhibitor
Table 7. Individual example with different sets on weights in ranking 
calculation
i) Ranking calculation with normalized disability weights only, and without patient 








BP medication use Yes
Currently smoking No
Oral diabetes medication use Yes
Total cholesterol (mg/dL) 181 (4.8 mmol/L)
HDL cholesterol (mg/dL) 61 (1.4 mmol/L)
Hemoglobin A1c (%) 6.1 (51.5 mmol/mol)
Serum creatinine (mg/DL) 0.63 (53.0 μmol/L)
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Urine albumin creatinine ratio (mg/g) 301.6
CVD history No
CVD risk (10-yr risk, %)
  Myocardial infarction 4
  Stroke 1
Microvascular risk (10-yr risk, %)
  Nephropathy 5
  Retinopathy 6
  Neuropathy 6













ii) Ranking calculation with patient preference weights only (patients would 
consider each outcome equally), without normalized disability weights assigned 
to decision criteria.
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Conceptual illustration of the decision-making model
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Figure 2. Therapy recommendations based on preference variations
The proportion of the NHANES population recommended each medication based on 
variations in their preferences. The results show the proportion of time that a medication 
class is the first-ranked therapy from the model, if a patient only selects one decision 
criterion in the decision-making process. The online decision tool enables multiple decision 
criteria to be weighted.41 Legend: “HbA1c”: hemoglobin A1c; “body weight”: weight gain; 
“hypoglycemia”: risk of hypoglycemia; “cost”: out of pocket patient drug cost for 3 months; 
“daily testing”: desire to avoid daily glucose testing; “injection”: desire to avoid parenteral 
medications.
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Table 3.
Incremental quality-adjusted-life-years converting from the current second-line treatment (e.g., sulfonylurea) 
to MCDA recommended treatment
Drug class NHANES Population, % Incremental QALYs (95% CI)
Base-case network meta-
analysis22




All persons 100.0 0.036 (0.032, 0.039) 0.064 (0.061, 0.067)
Age
20-39 6.9 0.009 (0.004, 0.014) 0.014 (0.009, 0.019)
40-59 28.5 0.024 (0.020, 0.028) 0.034 (0.030, 0.037)
60+ 64.6 0.043 (0.038, 0.048) 0.082 (0.077, 0.087)
Sex
Male 50.3 0.042 (0.037, 0.048) 0.078 (0.073, 0.083)
Female 49.7 0.028 (0.024, 0.033) 0.049 (0.045, 0.053)
Race
Black 50.2 0.038 (0.033, 0.043) 0.070 (0.066, 0.074)
Non-Black 48.8 0.033 (0.028, 0.037) 0.058 (0.054, 0.062)
Diabetes duration
< 10 years 56.6 0.034 (0.030, 0.038) 0.058 (0.054, 0.062)
≥10 years 43.4 0.037 (0.031,0.043) 0.071 (0.066, 0.076)
HbA1c
< 6.5% 38.8 0.028 (0.021, 0.033) 0.058 (0.053, 0.063)
6.5% – 7.9% 40.3 0.038 (0.032, 0.044) 0.069 (0.064, 0.074)
8.0% - 9.4% 12.5 0.040 (0.030, 0.049) 0.066 (0.057, 0.075)
≥ 9.5% 8.4 0.052 (0.041, 0.063) 0.063 (0.052, 0.074)
10-year cardiovascular risk 
(myocardial infarction or stroke)
< 10% 41.6 0.018 (0.014, 0.021) 0.030 (0.026, 0.034)
10% – 20% 36.5 0.037 (0.031, 0.044) 0.071 (0.065, 0.077)
≥ 20% 21.9 0.066 (0.056, 0.076) 0.118 (0.108, 0.128)
10-year composite Microvascular 
disease risk
< 20% 30.0 0.018 (0.014, 0.023) 0.033 (0.029, 0.037)
20% – 30% 35.9 0.029 (0.024, 0.035) 0.059 (0.053, 0.065)
≥ 30% 34.1 0.057 (0.049, 0.064) 0.096 (0.089, 0.107)
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Table 4.
Individual examples of type 2 diabetes patients from the U.S. National Health and Nutrition Examination 
Survey (2003-2014, N = 1,107), incorporating results from recent trials on improved cardiovascular disease 
outcomes from some second-line glycemic therapies 42
Covariate Person 1 Person 2 Person 3 Person 4
Sex Female Female Male Male
Age 47 44 63 66
Race Hispanic Black White Black
SBP (mmHg) 137 95 128 116
Statin use No No No No
Anticoagulant use No No No No
BP medication use No Yes Yes Yes
Currently smoking No Yes No No
Oral diabetes medication use No No No No
































Urine albumin creatine ratio (mg/g) 54.2 7.6 68.8 60.0
CVD history Yes Yes No Yes
CVD risk (10-yr risk, %) Low High Low High
  Myocardial infarction 8 12 7 56
  Stroke 2 2 5 34
Microvascular risk (10-yr risk, %) Low Low High High
  Nephropathy 8 7 23 58
  Retinopathy 6 5 17 26
  Neuropathy 7 7 16 23
Drug ranking score (95% CI) based on network meta-analysis22 *
1st, ranking score normalized to 1 [uncertainty scale 
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Preference weights: Only macrovascular and microvascular outcomes were considered important, accounting for the disability weights associated 
with disease outcomes.36-40
*
Drug ranking scores were normalized by the best ranking score. Score of 1 refers to the best ranking score, and the scores for other drugs are 
ranking scores relative the best ranking score. 95% confidence intervals were generated based on the uncertainty around the treatment effect 
estimates from the network meta-analysis.
TZD: Thiazolidinedione; SU: Sulfonylurea; GLP-1RA; GLP-1 agonist; SGLT-2-I; SGLT-2 inhibitor; DPP-4-I; DPP-4 inhibitor
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